• 1
    Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119:e21181.
  • 2
    George MG, Tong X, McGruder H et al. Paul Coverdell National Acute Stroke Registry Surveillance – four states, 2005–2007. MMWR Surveill Summ 2009; 58:123.
  • 3
    Bambauer KZ, Johnston SC, Bambauer DE, Zivin JA. Reasons why few patients with acute stroke receive tissue plasminogen activator. Arch Neurol 2006; 63:661664.
  • 4
    Barber PA, Zhang J, Demchuk AM et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001; 56:10151020.
  • 5
    Smith EE, Abdullah AR, Petkovska I et al. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 2005; 36:24972499.
  • 6
    Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359:13171329.
  • 7
    Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009; 40:29452948.
  • 8
    Reeves MJ, Arora S, Broderick JP et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke 2005; 36:12321240.
  • 9
    Rymer MM, Thrutchley DE. Organizing regional networks to increase acute stroke intervention. Neurol Res 2005; 27(Suppl. 1):S916.
  • 10
    StataCorp. Stata Statistical Software. Release 11. College Station, TX, StataCorp LP, 2009.
  • 11
    Kleindorfer D, Khoury J, Broderick JP et al. Temporal trends in public awareness of stroke: warning signs, risk factors, and treatment. Stroke 2009; 40:25022506.
  • 12
    Chernyshev OY, Martin-Schild S, Albright KC et al. Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia. Neurology 2010; 74:13401345.
  • 13
    Hassan AE, Hassanzadeh B, Tohidi V et al. Very mild stroke patients benefit from intravenous tissue plasminogen activator without increase of intracranial hemorrhage. South Med J 2010; 103:398402.
  • 14
    Hassan AE, Zacharatos H, Hassanzadeh B et al. Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator? J Stroke Cerebrovasc Dis 2010; 19:116120.
  • 15
    Faden R, Faden A. False belief and the refusal of medical treatment. J Med Ethics 1977; 3:133136.
  • 16
    Sharp HM, Bryant KN. Ethical issues in dysphagia: when patients refuse assessment or treatment. Semin Speech Lang 2003; 24:285299.